(MRK) Merck - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58933Y1055
Stock: Oncology, Vaccines, Antibiotics, Cardiovascular, Veterinary
Total Rating 66
Risk 86
Buy Signal -0.14
| Risk 5d forecast | |
|---|---|
| Volatility | 28.9% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | 19.27 |
| Character TTM | |
|---|---|
| Beta | 0.208 |
| Beta Downside | -0.010 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.44% |
| CAGR/Max DD | 0.14 |
EPS (Earnings per Share)
Revenue
Description: MRK Merck March 01, 2026
Merck & Co., Inc. (NYSE: MRK) is a global healthcare leader that markets a broad portfolio of human pharmaceuticals-including flagship immuno-oncology drug Keytruda and diabetes treatments Januvia/Janumet-as well as a wide range of veterinary vaccines and companion-animal products. The company also leverages a network of collaborations, such as co-development deals with AstraZeneca on Lynparza and with Daiichi Sankyo on ADC candidates, to expand its pipeline across oncology and specialty therapeutics.
In its most recent fiscal year, Merck generated $59.3 billion in revenue, driven largely by Keytruda’s $15.5 billion sales run-rate, and reported earnings per share of $8.78. The firm maintained a dividend yield of roughly 2.9% and invested $9.4 billion in R&D, underscoring its commitment to pipeline growth. Recent FDA approvals for the COVID-19 vaccine Vaxneuvance and the oncology drug Delstrigo have further bolstered its product pipeline.
Sector-wide, the aging U.S. population and rising demand for immuno-oncology therapies continue to lift the pharmaceuticals industry, while consolidation among biotech firms creates partnership opportunities that Merck is well-positioned to capture. For a deeper dive into MRK’s valuation metrics, you might explore the analysis on ValueRay.
Headlines to watch out for
- Keytruda sales growth drives oncology revenue expansion
- Gardasil vaccine demand boosts prophylactic portfolio
- Research and development pipeline success impacts future earnings
- Generic drug competition threatens mature product sales
- Regulatory approvals and setbacks influence drug market access
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 18.25b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -6.42 > 1.0 |
| NWC/Revenue: 23.36% < 20% (prev 16.15%; Δ 7.22% < -1%) |
| CFO/TA 0.12 > 3% & CFO 16.47b > Net Income 18.25b |
| Net Debt (35.97b) to EBITDA (26.31b): 1.37 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.49b) vs 12m ago -2.09% < -2% |
| Gross Margin: 81.50% > 18% (prev 0.76%; Δ 8.07k% > 0.5%) |
| Asset Turnover: 51.20% > 50% (prev 54.79%; Δ -3.60% > 0%) |
| Interest Coverage Ratio: 16.23 > 6 (EBITDA TTM 26.31b / Interest Expense TTM 1.36b) |
Altman Z'' 4.51
| A: 0.11 (Total Current Assets 43.52b - Total Current Liabilities 28.33b) / Total Assets 136.87b |
| B: 0.53 (Retained Earnings 73.08b / Total Assets 136.87b) |
| C: 0.17 (EBIT TTM 22.01b / Avg Total Assets 126.99b) |
| D: 0.84 (Book Value of Equity 70.58b / Total Liabilities 84.20b) |
| Altman-Z'' Score: 4.51 = AA |
Beneish M -2.86
| DSRI: 1.22 (Receivables 12.68b/10.28b, Revenue 65.01b/64.17b) |
| GMI: 0.94 (GM 81.50% / 76.32%) |
| AQI: 1.04 (AQ_t 0.49 / AQ_t-1 0.47) |
| SGI: 1.01 (Revenue 65.01b / 64.17b) |
| TATA: 0.01 (NI 18.25b - CFO 16.47b) / TA 136.87b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of MRK shares?
As of March 21, 2026, the stock is trading at USD 114.18 with a total of 36,354,772 shares traded.
Over the past week, the price has changed by -0.51%, over one month by -5.92%, over three months by +9.84% and over the past year by +24.91%.
Over the past week, the price has changed by -0.51%, over one month by -5.92%, over three months by +9.84% and over the past year by +24.91%.
Is MRK a buy, sell or hold?
Merck has received a consensus analysts rating of 4.04.
Therefore, it is recommended to buy MRK.
- StrongBuy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 127.8 | 11.9% |
| Analysts Target Price | 127.8 | 11.9% |
MRK Fundamental Data Overview March 20, 2026
P/E Trailing = 15.728
P/E Forward = 22.5734
P/S = 4.3545
P/B = 5.4457
P/EG = 3.5257
Revenue TTM = 65.01b USD
EBIT TTM = 22.01b USD
EBITDA TTM = 26.31b USD
Long Term Debt = 46.75b USD (from longTermDebt, last quarter)
Short Term Debt = 2.88b USD (from shortTermDebt, last quarter)
Debt = 50.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.97b USD (from netDebt column, last quarter)
Enterprise Value = 319.06b USD (283.09b + Debt 50.53b - CCE 14.56b)
Interest Coverage Ratio = 16.23 (Ebit TTM 22.01b / Interest Expense TTM 1.36b)
EV/FCF = 25.81x (Enterprise Value 319.06b / FCF TTM 12.36b)
FCF Yield = 3.87% (FCF TTM 12.36b / Enterprise Value 319.06b)
FCF Margin = 19.01% (FCF TTM 12.36b / Revenue TTM 65.01b)
Net Margin = 28.08% (Net Income TTM 18.25b / Revenue TTM 65.01b)
Gross Margin = 81.50% ((Revenue TTM 65.01b - Cost of Revenue TTM 12.03b) / Revenue TTM)
Gross Margin QoQ = 92.71% (prev 77.69%)
Tobins Q-Ratio = 2.33 (Enterprise Value 319.06b / Total Assets 136.87b)
Interest Expense / Debt = 0.81% (Interest Expense 411.0m / Debt 50.53b)
Taxrate = 13.39% (458.0m / 3.42b)
NOPAT = 19.06b (EBIT 22.01b * (1 - 13.39%))
Current Ratio = 1.54 (Total Current Assets 43.52b / Total Current Liabilities 28.33b)
Debt / Equity = 0.96 (Debt 50.53b / totalStockholderEquity, last quarter 52.61b)
Debt / EBITDA = 1.37 (Net Debt 35.97b / EBITDA 26.31b)
Debt / FCF = 2.91 (Net Debt 35.97b / FCF TTM 12.36b)
Total Stockholder Equity = 50.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.37% (Net Income 18.25b / Total Assets 136.87b)
RoE = 36.19% (Net Income TTM 18.25b / Total Stockholder Equity 50.45b)
RoCE = 22.65% (EBIT 22.01b / Capital Employed (Equity 50.45b + L.T.Debt 46.75b))
RoIC = 21.02% (NOPAT 19.06b / Invested Capital 90.69b)
WACC = 5.77% (E(283.09b)/V(333.62b) * Re(6.68%) + D(50.53b)/V(333.62b) * Rd(0.81%) * (1-Tc(0.13)))
Discount Rate = 6.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 85.77% ; FCFF base≈14.65b ; Y1≈13.87b ; Y5≈13.15b
[DCF] Fair Price = 145.2 (EV 394.95b - Net Debt 35.97b = Equity 358.98b / Shares 2.47b; r=5.90% [WACC]; 5y FCF grow -6.93% → 2.90% )
EPS Correlation: 20.65 | EPS CAGR: -1.27% | SUE: 0.42 | # QB: 0
Revenue Correlation: 65.66 | Revenue CAGR: 0.83% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.94 | Chg7d=+0.000 | Chg30d=-0.159 | Revisions Net=+1 | Analysts=18
EPS current Year (2026-12-31): EPS=5.12 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-5 | Growth EPS=-43.0% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.78 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=+0 | Growth EPS=+90.9% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.4%)
[Growth] Growth Spread = +2.1% (Analyst 3.7% - Implied 1.6%)
P/E Forward = 22.5734
P/S = 4.3545
P/B = 5.4457
P/EG = 3.5257
Revenue TTM = 65.01b USD
EBIT TTM = 22.01b USD
EBITDA TTM = 26.31b USD
Long Term Debt = 46.75b USD (from longTermDebt, last quarter)
Short Term Debt = 2.88b USD (from shortTermDebt, last quarter)
Debt = 50.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.97b USD (from netDebt column, last quarter)
Enterprise Value = 319.06b USD (283.09b + Debt 50.53b - CCE 14.56b)
Interest Coverage Ratio = 16.23 (Ebit TTM 22.01b / Interest Expense TTM 1.36b)
EV/FCF = 25.81x (Enterprise Value 319.06b / FCF TTM 12.36b)
FCF Yield = 3.87% (FCF TTM 12.36b / Enterprise Value 319.06b)
FCF Margin = 19.01% (FCF TTM 12.36b / Revenue TTM 65.01b)
Net Margin = 28.08% (Net Income TTM 18.25b / Revenue TTM 65.01b)
Gross Margin = 81.50% ((Revenue TTM 65.01b - Cost of Revenue TTM 12.03b) / Revenue TTM)
Gross Margin QoQ = 92.71% (prev 77.69%)
Tobins Q-Ratio = 2.33 (Enterprise Value 319.06b / Total Assets 136.87b)
Interest Expense / Debt = 0.81% (Interest Expense 411.0m / Debt 50.53b)
Taxrate = 13.39% (458.0m / 3.42b)
NOPAT = 19.06b (EBIT 22.01b * (1 - 13.39%))
Current Ratio = 1.54 (Total Current Assets 43.52b / Total Current Liabilities 28.33b)
Debt / Equity = 0.96 (Debt 50.53b / totalStockholderEquity, last quarter 52.61b)
Debt / EBITDA = 1.37 (Net Debt 35.97b / EBITDA 26.31b)
Debt / FCF = 2.91 (Net Debt 35.97b / FCF TTM 12.36b)
Total Stockholder Equity = 50.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.37% (Net Income 18.25b / Total Assets 136.87b)
RoE = 36.19% (Net Income TTM 18.25b / Total Stockholder Equity 50.45b)
RoCE = 22.65% (EBIT 22.01b / Capital Employed (Equity 50.45b + L.T.Debt 46.75b))
RoIC = 21.02% (NOPAT 19.06b / Invested Capital 90.69b)
WACC = 5.77% (E(283.09b)/V(333.62b) * Re(6.68%) + D(50.53b)/V(333.62b) * Rd(0.81%) * (1-Tc(0.13)))
Discount Rate = 6.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 85.77% ; FCFF base≈14.65b ; Y1≈13.87b ; Y5≈13.15b
[DCF] Fair Price = 145.2 (EV 394.95b - Net Debt 35.97b = Equity 358.98b / Shares 2.47b; r=5.90% [WACC]; 5y FCF grow -6.93% → 2.90% )
EPS Correlation: 20.65 | EPS CAGR: -1.27% | SUE: 0.42 | # QB: 0
Revenue Correlation: 65.66 | Revenue CAGR: 0.83% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.94 | Chg7d=+0.000 | Chg30d=-0.159 | Revisions Net=+1 | Analysts=18
EPS current Year (2026-12-31): EPS=5.12 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-5 | Growth EPS=-43.0% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.78 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=+0 | Growth EPS=+90.9% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.4%)
[Growth] Growth Spread = +2.1% (Analyst 3.7% - Implied 1.6%)